Analysis of HSPD1 Gene Expression and Its Clinical Significance in Lung Adenocarcinoma Through Bioinformatics

DOI: https://doi.org/10.62517/jmhs.202605109

Author(s)

Chunling Wang*

Affiliation(s)

Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, Nanchong, China

Abstract

Objective: To clarify the expression, clinical significance, and molecular mechanism of HSPD1 in lung adenocarcinoma (LUAD), and to establish a foundation for predictive evaluation and precision treatment of LUAD. Methods: Based on the TCGA and GEPIA databases, the expression differences of HSPD1 in LUAD were analyzed; combined with clinical information, the correlation between HSPD1 expression and clinical features of LUAD patients such as tumor stage and race was explored; using the Kaplan-Meier Plotter database, the impact of HSPD1 on the overall survival and first progression-free survival of patients was evaluated; through the TIMER2.0 database, the association between HSPD1 expression, copy number variation, and tumor immune cell infiltration was analyzed; with the help of the GeneMANIA database, core interacting genes of HSPD1 were screened, and GO, KEGG enrichment analysis was performed using the R language clusterProfiler package to analyze its molecular regulation pathways. Results: HSPD1 was significantly highly expressed in LUAD and various tumors, and the consistency was verified at both transcriptomic and proteomic levels (P<0.05); its expression increased with the progression of LUAD stage (P<0.05), and was significantly associated with patient race, gender, and age (P<0.05). Patients with high HSPD1 expression had shorter overall survival and increased risk of disease progression (P<0.05), and its expression showed a significant inverse relationship with B cell and CD4+ T cell infiltration (P<0.05), and copy number amplification could further reduce immune cell infiltration. 20 core HSPD1 interacting genes were screened, which are mainly involved in amino acid metabolism, protein folding, and other processes and related pathways. Conclusion: HSPD1 is highly expressed in LUAD, closely related to tumor stage and patient prognosis, and may participate in the progression of LUAD by regulating immune cell infiltration and amino acid metabolism pathways. This molecule may serve as a diagnostic indicator and treatment focus for lung adenocarcinoma.

Keywords

HSPD1 Gene Expression; Clinical Significance; Lung Adenocarcinoma; Bioinformatics

References

[1] Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7-30. [2] Bade, B.C. and C.S. Dela Cruz, Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med, 2020. 41(1): p. 1-24. [3] Paez, J.G., et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004. 304(5676): p. 1497-500. [4] Wang, M., et al., Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases. J Inflamm Res, 2022. 15: p. 3083-3094. [5] Omidi, A., et al., Heat-shock proteins, oxidative stress, and antioxidants in one-humped camels. Trop Anim Health Prod, 2023. 56(1): p. 29. [6] Wang, X., et al., [Retracted] MicroRNA‑454 inhibits the malignant biological behaviours of gastric cancer cells by directly targeting mitogen‑activated protein kinase 1. Oncol Rep, 2022. 47(4). [7] Grzes, M., et al., A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. Cancers (Basel), 2020. 12(6). [8] Dong, S., et al., MMP28 recruits M2-type tumor-associated macrophages through MAPK/JNK signaling pathway-dependent cytokine secretion to promote the malignant progression of pancreatic cancer. J Exp Clin Cancer Res, 2025. 44(1): p. 60. [9] Li, F., et al., Relationship Between CNVs and Immune Cells Infiltration in Gastric Tumor Microenvironment. Front Genet, 2022. 13: p. 869967. [10] Tomczak, K., P. Czerwińska, and M. Wiznerowicz, The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn), 2015. 19(1a): p. A68-77. [11] Li, T., et al., TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res, 2017. 77(21): p. e108-e110. [12] Tang, Z., et al., GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017. 45(W1): p. W98-w102. [13] Chandrashekar, D.S., et al., UALCAN: An update to the integrated cancer data analysis platform. Neoplasia, 2022. 25: p. 18-27. [14] Gomes, A.P., et al., Kaplan-Meier Survival Analysis: Practical Insights for Clinicians. Acta Med Port, 2024. 37(4): p. 280-285. [15] Franz, M., et al., GeneMANIA update 2018. Nucleic Acids Res, 2018. 46(W1): p. W60-w64. [16] Luo, G., et al., Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med, 2025. 13(4): p. 348-363. [17] Comprehensive molecular profiling of lung adenocarcinoma. Nature, 2014. 511(7511): p. 543-50. [18] Ciocca, D.R. and S.K. Calderwood, Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones, 2005. 10(2): p. 86-103. [19] Yang, W., et al., Co-expression Network Analysis Identified Key Proteins in Association With Hepatic Metastatic Colorectal Cancer. Proteomics Clin Appl, 2019. 13(6): p. e1900017. [20] Parma, B., et al., Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting. J Exp Clin Cancer Res, 2021. 40(1): p. 248. [21] Lv, B., et al., Immunotherapy: Reshape the Tumor Immune Microenvironment. Front Immunol, 2022. 13: p. 844142.